# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cantor Fitzgerald analyst Louise Chen reiterates Eli Lilly (NYSE:LLY) with a Overweight and maintains $885 price target.
Key Takeaways: Sales approval for the company’s anti-obesity drug mazdutide may drag out beyond this year, potentially allow...
FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked.
Shares of Eli Lilly hit resistance at the $955 level. Now they are heading lower. These moves are due to investor psychology.
Criminals distribute fake Ozempic by forging batch numbers. Novo Nordisk suspects one source in global counterfeiting operation...